BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31901178)

  • 1. Phenotypical and potential functional characteristics of different immune cells expressing CD28H/B7-H5 and their relationship with cancer prognosis.
    Zhong C; Lang Q; Yu J; Wu S; Xu F; Tian Y
    Clin Exp Immunol; 2020 Apr; 200(1):12-21. PubMed ID: 31901178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma.
    Chen Q; Wang J; Chen W; Zhang Q; Wei T; Zhou Y; Xu X; Bai X; Liang T
    Cancer Sci; 2019 Feb; 110(2):530-539. PubMed ID: 30548441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7
    Zhuang X; Long EO
    Cancer Immunol Res; 2019 Jun; 7(6):939-951. PubMed ID: 31018957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD28H expression identifies resident memory CD8 + T cells with less cytotoxicity in human peripheral tissues and cancers.
    Tian Y; Sun Y; Gao F; Koenig MR; Sunderland A; Fujiwara Y; Torphy RJ; Chen L; Edil BH; Schulick RD; Zhu Y
    Oncoimmunology; 2019; 8(2):e1538440. PubMed ID: 30713797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H5 costimulates human T cells via CD28H.
    Zhu Y; Yao S; Iliopoulou BP; Han X; Augustine MM; Xu H; Phennicie RT; Flies SJ; Broadwater M; Ruff W; Taube JM; Zheng L; Luo L; Zhu G; Chen J; Chen L
    Nat Commun; 2013; 4():2043. PubMed ID: 23784006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
    Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
    Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of B7H5/CD28H is associated with worse survival in human gastric cancer.
    Hu C; Xu Z; Chen S; Lv H; Wang Y; Wang X; Mo S; Shi C; Wei S; Hu L; Chen W; Cheng X
    J Cell Mol Med; 2020 Jan; 24(2):1360-1369. PubMed ID: 31883303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New B7 Family Checkpoints in Human Cancers.
    Ni L; Dong C
    Mol Cancer Ther; 2017 Jul; 16(7):1203-1211. PubMed ID: 28679835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotype and tissue distribution of CD28H
    Crespo J; Vatan L; Maj T; Liu R; Kryczek I; Zou W
    Oncoimmunology; 2017; 6(12):e1362529. PubMed ID: 29209568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B7-H7 Is Inducible on T Cells to Regulate Their Immune Response and Serves as a Marker for Exhaustion.
    Luu K; Schwarz H; Lundqvist A
    Front Immunol; 2021; 12():682627. PubMed ID: 34140952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma.
    Zheng S; Luo X; Dong C; Zheng D; Xie J; Zhuge L; Sun Y; Chen H
    Int J Cancer; 2018 Nov; 143(10):2592-2601. PubMed ID: 30152019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy.
    Khan M; Arooj S; Wang H
    Front Immunol; 2021; 12():651634. PubMed ID: 34531847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The B7 Family Member B7-H6: a New Bane of Tumor.
    Chen Y; Mo J; Jia X; He Y
    Pathol Oncol Res; 2018 Oct; 24(4):717-721. PubMed ID: 29086181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of B7 co-stimulatory molecules by astrocytes correlates with T cell activation and cytokine production.
    Soos JM; Ashley TA; Morrow J; Patarroyo JC; Szente BE; Zamvil SS
    Int Immunol; 1999 Jul; 11(7):1169-79. PubMed ID: 10383950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
    Fiegler N; Textor S; Arnold A; Rölle A; Oehme I; Breuhahn K; Moldenhauer G; Witzens-Harig M; Cerwenka A
    Blood; 2013 Aug; 122(5):684-93. PubMed ID: 23801635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant expression of B7-H4 and B7-H5 contributes to the development of cutaneous squamous cell carcinoma.
    Chen L; Zhou B; Tang M; Yao Y; Zhao Y; Hu Y; Lin Y; Ji J; Jiao Q
    Arch Dermatol Res; 2024 Jun; 316(7):382. PubMed ID: 38850312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
    Lee YH; Martin-Orozco N; Zheng P; Li J; Zhang P; Tan H; Park HJ; Jeong M; Chang SH; Kim BS; Xiong W; Zang W; Guo L; Liu Y; Dong ZJ; Overwijk WW; Hwu P; Yi Q; Kwak L; Yang Z; Mak TW; Li W; Radvanyi LG; Ni L; Liu D; Dong C
    Cell Res; 2017 Aug; 27(8):1034-1045. PubMed ID: 28685773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression, function, and clinical relevance of B7 family members in cancer.
    Seliger B; Quandt D
    Cancer Immunol Immunother; 2012 Aug; 61(8):1327-41. PubMed ID: 22695874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the B7 family of co-stimulatory molecules: successes and challenges.
    Podojil JR; Miller SD
    BioDrugs; 2013 Feb; 27(1):1-13. PubMed ID: 23329394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the Novel Costimulatory Molecule B7-H5 in Pancreatic Cancer.
    Byers JT; Paniccia A; Kaplan J; Koenig M; Kahn N; Wilson L; Chen L; Schulick RD; Edil BH; Zhu Y
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1574-9. PubMed ID: 25519928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.